Healthcare

Nyrada (ASX:NYR) has progressed its lead cardiovascular drug candidate Xolatryp into human testing after dosing the first patient in its Phase IIa PROTECT-MI trial.

Orthocell (ASX:OCC) has reported its strongest financial year to date, supported by increasing adoption of Remplir, its collagen nerve-repair wrap used in surgical procedures.

CSL Limited (ASX:CSL) is progressing a next-generation plasma manufacturing technology aimed at increasing immunoglobulin production from existing plasma supplies.

Clarity Pharmaceuticals (ASX:CU6) is continuing to build the clinical, manufacturing and regulatory infrastructure required to support potential commercialisation of its radiopharmaceutical platform.

Clinuvel Pharmaceuticals (ASX:CUV) is repositioning its global operations towards the United States through a Nasdaq listing upgrade, planned headquarters relocation and increased focus on American market opportunities.

Dimerix (ASX:DXB) has expanded the commercial pathway for its lead drug candidate DMX-200 through an exclusive licensing agreement with Everest Medicines covering key Asian markets.

EVE Health Group (ASX:EVE) has moved its lead men’s health product, Libbo, into its first clinical study as the company progresses towards potential regulatory registration and commercialisation.